About Our Sarcoidosis Program
Every sarcoidosis case is different, so Mount Sinai physicians personalize the most effective treatment plan for each patient. Approximately 3,000 sarcoidosis patients actively visit Mount Sinai, and depending on the type and severity of each individual case, we strive to reverse the disease’s progression, manage symptoms, or provide the tools needed to best cope with the disorder. Through unique diagnostic tests, advanced treatments, and a multidisciplinary approach, we give our patients the resources, support, and care they need to achieve the best possible quality of life.
Providing Advanced Sarcoidosis Care
Because Mount Sinai’s Sarcoidosis Program sees a uniquely high volume of patients with the most complex cases, we’ve developed a rare level of experience and skill in diagnosing and treating the most challenging forms of this disease.
We are the only medical center in the United States offering the Kveim-Siltzbach skin test, a noninvasive diagnostic test for sarcoidosis that our specialists are skilled in administering and interpreting. Our physicians are also experienced in administering immunomodulatory medication therapies (including alternatives to Prednisone) as well as evaluating patients for definitive treatments, such as organ transplantation. The care we provide is enhanced by the fact that Mount Sinai is an NIH Center of Excellence for research in sarcoidosis.
Hosting a Top Sarcoidosis Support Group
Our Sarcoidosis Program is pleased to offer patients and their loved ones additional care and guidance through our active support group. Regular meetings allow patients to ask questions, learn about new diagnoses and therapies, and meet the members of our multidisciplinary staff who participate in their care.
Through our support group, advanced diagnostics, research, treatments, and the expertise of our multidisciplinary team, Mount Sinai’s Sarcoidosis Program strives to give patients the answers, therapies, and tools they need to manage this disease as successfully as possible.